Back to search
FDAFDA · Food and drugs·Recall number Z-0547-2014

FastPack Total PSA Immunoassay Chemilunescence assay for the determination of Total PSA. FastPack Total PSA Immunoassay is a paramagnetic particle immunoassay for the in vitro quantitative determination of prostate-specific antigen (PSA) in human serum and plasma as an aid in the management of patients with prostate cancer. The FastPack Total PSA Immunoassay is designed for use with the FastPack System.

Published December 25, 2013 · Recall initiated: November 8, 2013

Summary

FDA records medical device Class II recall Z-0547-2014, published December 25, 2013 and initiated November 8, 2013. Recalling firm: Qualigen Inc; Status: Terminated; Reported quantity: 182; Lot: Total PSA: Catalog Number 25000040. Lot Number 1309038-10P Exp Date 6/26/2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Qualigen initiated this recall because the FastPack kit may cause lower than expected results due to a manufacturing defect.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Qualigen Inc
Distributor
US Distribution to states of: AL, CA, KS, KY, IN, MA, NC, NY, NV, OK, SC, TN, TX, UT, VA, and WA.
Lot
Total PSA: Catalog Number 25000040. Lot Number 1309038-10P Exp Date 6/26/2013.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was FastPack Total PSA Immunoassay Chemilunescence assay for the determination of Total PSA. FastPack Total PSA Immunoassay is a paramagnetic particle immunoassay for the in vitro quantitative determination of prostate-specific antigen (PSA) in human serum and plasma as an aid in the management of patients with prostate cancer. The FastPack Total PSA Immunoassay is designed for use with the FastPack System. recalled?

Yes. FDA published recall Z-0547-2014 on December 25, 2013. Reported hazard: Qualigen initiated this recall because the FastPack kit may cause lower than expected results due to a manufacturing defect.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone